Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Danielle Zitek

Physician Assistant Chandler, AZ Physician Assistant

NPI 1386239895 CMS profile 11268886

3200 S Alma School Rd Ste 204, Chandler, AZ 85248

Open in the dashboard

General payments

$24,119

379 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danielle Zitek of Chandler, AZ is reported in the CMS Open Payments database as having received $24,119 across 379 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,053 179
2024 General $5,015 126
2023 General $3,237 58
2022 General $742 12
2021 General $72 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danielle Zitek
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Danielle Zitek were reported at $15,053. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Danielle Zitek Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $72 $132 $37–$438 $132
2022 $742 $155 $48–$522 $149
2023 $3,237 $167 $52–$557 $160
2024 $5,015 $178 $55–$600 $164
2025 $15,053 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $6,642 34 payments
  2. Boston Scientific Corporation $5,644 110 payments
  3. Biosense Webster, Inc. $4,362 108 payments
  4. Medtronic, Inc. $3,928 56 payments
  5. Kestra Medical Technology Services, Inc. $1,334 20 payments
  6. Abbott Laboratories $1,103 32 payments
  7. Atricure, Inc. $587 12 payments
  8. Aziyo Biologics, Inc. $175 1 payment
  9. Baxter Healthcare $140 1 payment
  10. Janssen Pharmaceuticals, Inc $110 1 payment
  11. Other $93 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,782 353 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,470 7 payments
  3. Travel and Lodging $2,795 15 payments
  4. Education $72 4 payments
Products named General payments · program years 2021–2025
  1. LifeVest $6,642 34 payments
  2. Carto 3 $3,260 90 payments
  3. WATCHMAN FLX $1,755 51 payments
  4. General - Therapies $1,381 6 payments
  5. FARAPULSE $1,015 3 payments
  6. Assure WCD Cardiology/Vascular Diseases $915 9 payments
  7. QDOT MICRO $615 11 payments
  8. ATRICLIP LAA EXCLUSION SYSTEM $525 11 payments
  9. Assure WCD Cardiology $419 11 payments
  10. Micra $382 7 payments
  11. Other $3,763 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

367

Median for Physician Assistant: 241

Drug cost

$123,234

Median for Physician Assistant: $4,110

Branded share of claims

53.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 63 $72,600
Xarelto Rivaroxaban Brand 43 $45,314
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 12 $2,037
Flecainide Acetate Generic 21 $842
Metoprolol Succinate Generic 34 $775
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 23 $630
Clopidogrel Clopidogrel Bisulfate Brand 54 $295
Metoprolol Tartrate Generic 44 $235
Amiodarone Hcl Generic 12 $156
Amlodipine Besylate Generic 25 $119

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$61,544

Medicare's payments for the services billed

Medicare patients

291

Average age 77

Services billed

931

155 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 73%
Arthritis 52%
Ischemic heart disease 47%
Diabetes 38%
Heart failure 37%
Chronic kidney disease 35%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

379 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record